Homburger with CDR-Life on licensing agreement with Boehringer Ingelheim
Homburger advised CDR-Life on a new global licensing agreement with Boehringer Ingelheim, aimed at the development of an antibody-based molecule for autoimmune diseases.
The context
The agreement – which follows the companies’ collaboration on an investigational antibody fragment – sees CDR-Life being eligible for up to a total of CHF 456 m in payments, including CHF 38 m in upfront and near-term payments, plus tiered royalties on future sales.
The Homburger team
Luca Dal Molin (IP/IT, pictured) led the Homburger team on the matter, working alongside Richard Stäuber (regulatory) and Joel Fink (IP/IT).